建新股份(300107.SZ):子公司擬以不超1.5億元參與競拍滄州相關地塊
格隆匯 3 月 3日丨建新股份(300107.SZ)公佈,公司於2021年3月2日召開第五屆董事會第十一次會議審議通過了《關於全資子公司擬參與競拍土地使用權的議案》,同意全資子公司滄州建新瑞祥化學科技有限公司(“建新瑞祥”)以自有資金參與競拍滄州臨港經濟技術開發區地塊的土地使用權。同時,授權建新瑞祥管理層辦理此次競拍、購買相關手續並簽署相關文件。
建新瑞祥擬使用不超過人民幣1.5億元參與競拍位於滄州臨港經濟技術開發區地塊的土地使用權。根據地塊掛牌競拍程序,具體競拍面積以實際測量為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.